



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MMI-0100

Cat. No.:	HY-P3412
CAS No.:	1039342-24-9
Molecular Formula:	C ₉₈ H ₁₇₁ N ₃₇ O ₂₆
Molecular Weight:	2283.64
Sequence Shortening:	YARAAARQARAKALARQLGVAA
Target:	MAPKAPK2 (MK2)
Pathway:	MAPK/ERK Pathway
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (43.79 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	0.4379 mL	2.1895 mL	4.3790 mL
			5 mM	0.0876 mL	0.4379 mL	0.8758 mL
			10 mM	0.0438 mL	0.2189 mL	0.4379 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 14.29 mg/mL (6.26 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease ^[1] .
In Vitro	Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. ^[1] MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone ^[1] . MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100 ^[1] .

MMI-0100 does not induce EC apoptosis at any dose^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	human endothelial cell (EC) and smooth muscle cell (SMC)
Concentration:	0.25, 0.5, and 1 mM
Incubation Time:	24 hours
Result:	Slightly increased cell proliferation in both cell types compared to control cells.

In Vivo

MMI-0100 (100 μ M; 28 days) inhibits intimal hyperplasia in a mouse vein graft model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old C57Bl/6 wild type mice (intimal hyperplasia) ^[1]
Dosage:	100 μ M
Administration:	vein graft, 28 days
Result:	Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.

REFERENCES

[1]. Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. *Vascul Pharmacol.* Jan-Feb 2012;56(1-2):47-55.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA